News & Articles

Vaccine, trialed in 450 children, shows favorable safety profile and was well-tolerated

COVID-19 infections fell by 65% percent after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines in this large community surveillance study

A new Prenetics Innovation Technology Centre will be established for advanced molecular diagnostics

First rapid antigen test with performance data on children

Anti-cancer drug delivery to target tumor sites now becomes more effective with novel multi-stimuli-responsive drug delivery systems

An insider’s view on leveraging the latest single-cell technologies, including cell sorting and single-cell sequencing, to understand what drives response or resistance in checkpoint therapies

The company will receive up to $5 million in grant funds from DARPA as part of the agency’s Nucleic Acids On-Demand World-Wide Program to plan for and prevent the next viral pandemic

Dr. Tania Nolan outlines how her team is designing assays to identify new variants and why these are critical to managing the global response

AI could hold the key to more targeted treatment, according to new research

VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI

Dr. David Andrews, AstraZeneca, discusses the future of small-molecule drug discovery for PPIs

Watch world-leading scientists online, May 11-12, to discover the latest tools and techniques advancing COVID-19 research, immunotherapy development, drug screening, cancer diagnostics and more

The BinaxNOW Self-Test will be sold in 2-count packs for an MSRP of $23.99, making it an affordable over-the-counter COVID-19 rapid test available in the U.S.

Watch this on-demand webinar to learn about the mechanisms behind cancer treatments such as CAR-T cells, checkpoint inhibitors or adoptive T cell therapy

Reserve your place today for talks on topics ranging from food fraud, spatial infiltration and CRISPR to antibody and AAV gene therapies

CE marked assay based on well-established ELISA technology expands Euroimmun's offerings for labs that seek to understand immune response to COVID-19